NDAORALSOLUTION
Approved
Mar 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
REGLAN (metoclopramide hydrochloride) by Pfizer is clinical pharmacology metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. First approved in 1983.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REGLAN (metoclopramide HCl) is an oral gastrointestinal prokinetic agent approved in 1983 that treats nausea and vomiting by antagonizing dopamine receptors and enhancing upper GI tract motility. It works by sensitizing tissues to acetylcholine, increasing gastric contractions, relaxing the pyloric sphincter, and accelerating gastric emptying with onset in 30-60 minutes post-administration.
$88KPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal commercial spending; career roles focus on defensive maintenance rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not…
Worked on REGLAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.